Firebrick Pharma : Presents at Euroz Hartleys Healthcare Conference

For personal use only

26 July 2022

ASX Announcement

Firebrick Presents at Healthcare Investor Conference

• Firebrick presenting at Euroz Hartleys Healthcare Conference in Perth
• Conference to be attended by more than 20 institutional investors

Firebrick Pharma Limited (ASX:FRE) (Company or Firebrick) is pleased to advise that the Executive Chairman, Dr Peter Molloy, will be presenting an investor update on the Company at the Euroz Hartleys Healthcare Conference, taking place on Wednesday, 27 July, in Perth.

The Conference is scheduled to include presentations from nine leading ASX-listed biotech firms and is expected to be attended by more than 20 institutional investors as well as individual biotech investors.

The Firebrick investor presentation has been attached and will also be available on the Company's website for review by all shareholders.

This announcement was authorised for release by Dr Peter Molloy, Executive Chairman, Firebrick Pharma Limited.

- ENDS -

About Firebrick Pharma

Firebrick is a pharmaceutical company founded in 2012 to develop and commercialise a nasal spray treatment for the common cold based around the potential of povidone-iodine as a broad-spectrum antimicrobial agent. The Company subsequently developed Nasodine® Nasal Spray ("Nasodine") and owns numerous granted and pending patents, including a core patent family that covers the use of Nasodine for the treatment and prevention of the common cold. The Company also owns a patent family that covers the use of Nasodine for the prevention of pandemic viral diseases, including COVID-19. Firebrick is currently undertaking two major clinical trials: A Phase 2 trial of Nasodine in COVID-19 and a Phase 3 trial for Nasodine, to confirm its efficacy as a treatment for the common cold and support international approvals.

Media enquiries:

Heidi Cuthbert

+61 411 272 366 heidi.cuthbert@multiplier.com.au Investor enquiries: Investors@firebrickpharma.com

ersonal use only

INVESTOR PRESENTATION

EUROZ HARTLEYS HEALTHCARE CONFERENCE 27 JULY 2022

ersonal use only

This presentation is provided for information purposes only. The information in this presentation is in a summary form, does not purport to be complete and is not intended to be relied upon as advice to investors or other persons. The information contained in this presentation was prepared as of its date, and remains subject to change without notice. This presentation has been provided to you solely for the purpose of giving you background information about Firebrick Pharma Limited (Firebrick). This presentation is intended only for those persons to whom it is delivered personally by or on behalf of Firebrick. By attending this presentation, you represent and warrant that (i) if you are in Australia, you are a person to whom an offer of securities may be made without a disclosure document (as defined in the Corporations Act 2001 (Cth) (Corporations Act)) on the basis that you are exempt from the disclosure requirements of Part 6D.2 in accordance with Section 708(8) or 708(11) of the Corporations Act; (ii) if you are outside Australia, you are a person to whom an offer and issue of securities can be made outside Australia without registration, lodgement or approval of a formal disclosure document or other filing in accordance with the laws of that foreign jurisdiction. If you are not such a person, you are not entitled to attend this presentation. Please return this document and any copies and do not provide this document to any other person. This presentation is strictly confidential and is intended for the exclusive benefit of the person to which it is presented. It may not be reproduced, disseminated, quoted or referred to, in whole or in part, without the express consent of Firebrick. The recipient shall not disclose any of the information contained in this presentation to any other person without the prior written consent of Firebrick, which may be withheld in its absolute discretion.

No representation or warranty, express or implied, is made as to the accuracy, reliability, completeness or fairness of the information, opinions and conclusions contained in this presentation. Neither Firebrick, its related bodies corporate, shareholders or affiliates, nor any of their respective officers, directors, employees, related bodies corporate, affiliates, agents or advisers makes any representations or warranties that this presentation is complete or that it contains all material information about Firebrick or which a prospective investor or purchaser may require in evaluating a possible investment in Firebrick or an acquisition of its shares. To the maximum extent permitted by law, none of those persons accept any liability, including, without limitation, any liability arising out of fault or negligence for any loss arising from the use of information contained in this presentation or in relation to the accuracy or completeness of the information, statements, opinions or matters, express or implied, contained in, arising out of or derived from, or for omissions from, this presentation.

Certain statements in this presentation may constitute forward-looking statements or statements about future matters that are based upon information known and assumptions made as of the date of this presentation. Forward looking statements can generally be identified by the use of forward looking words such as, "expect", "anticipate", "likely", "intend", "should", "could", "may", "predict", "plan", "propose", "will", "believe", "forecast", "estimate", "target" and other similar expressions within the meaning of securities laws of applicable jurisdictions. Indications of, and guidance or outlook on, clinical trials, required regulatory approvals, future earnings or financial position or performance are also forward looking statements. These statements are subject to internal and external risks and uncertainties that may have a material effect on future business. Actual results may differ materially from any future results or performance expressed, predicted or implied by the statements contained in this presentation. As such, undue reliance should not be placed on any forward looking statement. Past performance is not necessarily a guide to future performance. Nothing contained in this presentation nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee, whether as to the past, present or future. No person is under any obligation to update this presentation at any time after its release to you.

The provision of this presentation is not a representation to you or any other person that an offer of securities will be made. Any prospective transaction would be undertaken solely on the basis of disclosure documentation prepared in accordance with applicable securities laws and regulations. The information presented in this presentation may differ materially in both content and presentation from that presented in any disclosure document prepared in connection with any prospective transaction. Firebrick reserves the right to alter the information contained in this presentation in any disclosure document prepared in respect of any prospective transaction from the form of this presentation accordingly.

This presentation is not, and does not constitute, an offer to sell or the solicitation, invitation or recommendation to purchase any securities in Firebrick and neither this presentation nor any of the information contained herein shall form the basis of any contract or commitment. In particular, this presentation does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States.

This presentation may not be reproduced or redistributed to any other person. This is a private communication and was not intended for public circulation or publication or for the use of any third party without the prior approval of Firebrick. All references to dollars, cents or $ in this presentation are to Australian currency, unless otherwise stated.

In receiving this presentation, each recipient agrees to the foregoing terms and conditions.

Potential for early approval and launch:

• Potential for early AU launch3
• Approvals in EU, US and other markets expected over the following 3-4 years
• Manufacturing ready, with local capacity to meet global demand

ersonal1 "Kill" indicates permanent elimination of viral infectivity. In in vitro studies, Nasodine has been

sh wn to eliminate the infectivity of representative strains of all viruses known to the common cold.

2 Betadine® is a registered trademark of Mundipharma AG and is not associated with Firebrick Pharma. PVP-I is widely available and can be supplied and used without license from Mundipharma or other party

3 Subject to a successful outcome in planned appeal to Administrative Appeals Tribunal (AAT).

Large addressable market

• Up to 20 billion colds p.a. worldwide
• Sales potential likely to be attractive to international distribution partners

Potential for high market adoption

• Very high consumer stated intent to purchase as soon as it is available
• Australian doctors and pharmacists indicate they will recommend and support it

Opportunities beyond the common cold

• Potential for expansion into hospital use, prevention and other indications
• Pandemic and biodefense potential
• Phase 2 COVID-19 clinical trial underway in South Africa

ersonal use only

A cold begins when a virus infects the

cells lining the nasal passages

EXISTING COLD TREATMENTS TARGET

SYMPTOM RELIEF ONLY

Temporaryrelief of symptoms

• Sore throat
• Runny nose
• Cough
• Allow the sufferer to "soldier on"

No impact on the viral causeof colds

Nasodine® Nasal Spray disperses through the nasal passages

to target the viruses that cause the infection

NASODINE NASAL SPRAY

TARGETS THE VIRAL CAUSE OF COLDS

Nasodine (if approved) will be the world's first approved nasal spray medicine that kills the viruses that cause colds

1st Phase 3 trial showed that Nasodine reduces overall cold severity (in key subsets) and impact of colds on daily activities in all subjects.